Daniel Steinberg

Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man.

Seppo Ylä‐Herttuala, Wulf Palinski, Michael E. Rosenfeld et al. · Journal of Clinical Investigation · 1989 · 1.9K citations · Full text

Vascular Disease, Pathology, Hyperlipidemia +19

Low density lipoprotein undergoes oxidative modification in vivo.

Wulf Palinski, Michael E. Rosenfeld, Seppo Ylä‐Herttuala et al. · Proceedings of the National Academy of Sciences · 1989 · 1.5K citations · Full text

Inflammation, Metabolic Syndrome, Low Density Lipoprotein +14

Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit.

T E Carew, Dawn C. Schwenke, Daniel Steinberg · Proceedings of the National Academy of Sciences · 1987 · 1K citations · Full text

Lipid Peroxidation, Hyperlipidemia, Oxidative Stress +18

Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins.

Tore Henriksen, Eileen M. Mahoney, Daniel Steinberg · Proceedings of the National Academy of Sciences · 1981 · 1K citations · Full text

Immunology, Hyperlipidemia, Low Density +20

Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions.

Seppo Ylä‐Herttuala, Beth Lipton, Michael E. Rosenfeld et al. · Proceedings of the National Academy of Sciences · 1991 · 877 citations · Full text

Vascular Disease, Immunology, Pathology +17